Vetstoria vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Veterinary Online Appointment Booking Platform
Real-time online appointment booking platform for veterinary practices; Dublin Ireland; raised $8M+; integrates with ezyVet, Provet Cloud, Cornerstone, and Avimark to synchronize 24/7 online bookings with clinic PIMS; serves thousands of vet practices globally.
About
Vetstoria is a real-time online appointment booking platform built specifically for veterinary practices, enabling pet owners to book appointments online 24/7 through a clinic's website without phone calls, while giving veterinary teams full control over appointment types, availability, and booking rules. Founded in 2016 and headquartered in Dublin, Ireland, Vetstoria has raised approximately $8 million and grown to serve thousands of veterinary practices globally in Europe, the US, Australia, and Asia, integrating with leading practice management systems to synchronize appointments in real time.\n\nVetstoria's booking platform connects directly to a clinic's veterinary information management system — including ezyVet, Provet Cloud, Cornerstone, Avimark, and others — so bookings made online appear immediately in the practice schedule without staff intervention, and availability shown to clients accurately reflects real-time slot availability. Clinics control which appointment types are bookable online, can set deposit requirements for high-demand slots, and can restrict booking access to existing clients only. Analytics provide data on booking conversion rates, booking source (website, Google, social), and time-of-day patterns.\n\nVetstoria competes with PetDesk, Vetster, and general appointment booking platforms adapted from human healthcare in the veterinary booking space. Its deep PIMS integrations and purpose-built veterinary rules engine — which can handle species-specific booking logic, new patient workflows, and emergency appointment routing — differentiate it from generic online booking tools. The platform helps veterinary practices capture after-hours booking demand, reduce front-desk call volume, and improve the client experience for digitally-oriented pet owners.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.